Certain studies have indicated that the overexpression of CD44 in tumors is correlated with increased resistance to radiation therapy and an elevated risk of local recurrence [32]–[34], whereas others have linked poor prognosis to CD44 downregulation on tumor cells, particularly in OSCC [35], [36]. This evidence concerns the gene CD44 and neoplasm.